Zobrazeno 1 - 10
of 22
pro vyhledávání: '"G G Sharvadze"'
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 17, Iss 3, Pp 79-84 (2018)
The review is focused on the issues of erectile dysfunction (ED) management by long term courses of continuous intake of the phosphodiesteraze-5 type (PDE5) inhibitors. ED is an actual problem of modern healthcare, prevalent and influencing negativel
Externí odkaz:
https://doaj.org/article/4b19bc224d944b688887b975462ec5b4
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 16, Iss 6, Pp 122-127 (2017)
RETRACTEDComorbidity of chronic non-communicable diseases is actual problem of modern medicine. It was found, that metabolic syndrome (MS) is pathogenetically related with erectile dysfunction (ED), hypogonadism, gout and urolithiasis, that is an exa
Externí odkaz:
https://doaj.org/article/c5abe21cece9446e8f836019b211de11
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 6, Iss 4, Pp 532-538 (2016)
The correlation of age-dependent reduction in sex hormones level and changes of cardiovascular system in men was shown recently. High prevalence and various clinical features of age-dependent hypogonadism demands to know diagnostics and management of
Externí odkaz:
https://doaj.org/article/ec9f8932f698410a89a49ddef095ff6f
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 6, Iss 5, Pp 691-696 (2016)
About 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of pati
Externí odkaz:
https://doaj.org/article/454d34be46f64f96bb7b3ac1606426c9
Publikováno v:
Андрология и генитальная хирургия, Vol 15, Iss 1, Pp 51-57 (2014)
The paper evaluates the impact of hormone replacement therapy (HRT) with androgens on cardiac metabolic indicators in men with high cardiovascular risk (CVR) and androgen deficiency state. An open-label randomized clinical trial enrolled 52 men aged
Externí odkaz:
https://doaj.org/article/ec4f9f04f03d4faebc2f7e4e8314f47a
Autor:
S H, Al-Shukri, D Yu, Pushkar, O I, Apolikhin, M S, Evdokimov, M I, Kogan, G G, Krivoborodov, O F, Kagan, S B, Petrov, A N, Poltoratskyi, I V, Kuzmin, G G, Sharvadze
Publikováno v:
Urologiia (Moscow, Russia : 1999). (6)
The analysis of the results of a multicenter, open, randomized comparative phase III clinical trial on the use of imidafenacin for treating patients with OAB was carried out. A clinical study was conducted according to GCP standards in 12 urological
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 6, Iss 5, Pp 691-696 (2016)
About 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of pati
Autor:
G. G. Sharvadze, M. N. Mamedov
Publikováno v:
Profilakticheskaya meditsina. 23:85
COVID-19 is caused by severe acute coronavirus 2 respiratory syndrome (SARS-CoV-2), which penetrates the cell by binding to the receptor angiotensin converting enzyme (ACE2) and priming cell protease, serine transmembrane proteinase (TMPRSS) Theoreti
Publikováno v:
Profilakticheskaya meditsina. 21:124
Publikováno v:
Scopus-Elsevier
The purpose of this study was to evaluate the influence of three different doses of atorvastatin on erectile function and androgen status in men with high risk of cardiovascular disease (CVD). In an open randomized comparative study with parallel gro